Products for Research Use Only
RegisterLogin

GSK-2636771

CAT: 0013-GTR19163380-01Size: 200 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0013-GTR19163380-01Size:200 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
GSK2636771 is a potent, orally bioavailable, PI3Kβ-selective inhibitor, sensitive to PTEN null cell lines. Phase 1/2a. (In Vitro) :GSK2636771 treatment causes cell viability significantly more decreased in the control cells (p110β-reliant PTEN-deficient PC3 prostate and BT549 and HCC70 breast cancer cell lines) than in PTEN-mutant and PTEN wild-type EEC cells. Inhibition of p110β by GSK2636771 or AZD6482 leads to a marked decrease of AKT phosphorylation only in the control prostate and breast cancer cell lines, whereas only marginal effects on AKT activation are observed in EEC cells. (In Vivo) :GSK2636771 is a p110β inhibitor, and the p110β primes cells for response to growth factor stimulation. While p110β inhibition suppresses cell and tumor growth, dual targeting of p110α/β enhances apoptosis and provides sustained tumor response in mice model.
CAS Number
1372540-25-4
Purity
>98% (HPLC)
Solubility
DMSO: 28 mg/mL (64.6 mM)
Smiles
CC1=NC2=C (C=C (C=C2C (O) =O) N2CCOCC2) N1CC1=C (C) C (=CC=C1) C (F) (F) F
Molecular Formula
C22H22F3N3O3
Molecular Weight
433.42
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.

Related Products

CatalogName
GTR19199176-01GSK-A
GTR19211454-01GSK-364735
GTR19208547-01GSK-1562590
GTR19205725-01GSK 366
GTR19200265-01GSK-3008348
GTR19198246-01GSK 894281
GTR19198213-01GSK-1034702
GTR19197846-01GSK-625433
GTR19197769-01GSK-894490A
GTR19194418-01GSK-1268997

Alternative Products

CatalogName
BG166668-01GSK 2636771
M11535-01GSK-2636771
IJD80607-01GSK 2636771 dihydrochloride
T25471-01GSK-A
MBS131437GSK163090 (GSK-163090; GSK 163090)
MBS131519GSK369796 (GSK-369796, GSK 369796)
A3450-5.1GSK-923295
BA4485-5.1GSK-25
B7751-100GSK 2193874
A3445-5.1GSK 525768A

Popular Products